title: Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation.
abstract: Tissue plasminogen activator is the only treatment option for stroke victims; however, it has to be administered within 4.5 h after symptom onset, making its use very limited. This report describes a unique target for effective treatment of stroke, even 12 h after onset, by the administration of αB-crystallin (Cryab), an endogenous immunomodulatory neuroprotectant. In Cryab(-/-) mice, there was increased lesion size and diminished neurologic function after stroke compared with wild-type mice. Increased plasma Cryab was detected after experimental stroke in mice and after stroke in human patients. Administration of Cryab even 12 h after experimental stroke reduced both stroke volume and inflammatory cytokines associated with stroke pathology. Cryab is an endogenous anti-inflammatory and neuroprotectant molecule produced after stroke, whose beneficial properties can be augmented when administered therapeutically after stroke.
authors.affiliation: Department of Neurosurgery, Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford Stroke Center, Stanford University School of Medicine, Stanford, CA 94305, USA.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Arac
authors.forename: Sara E
authors.initials: SE
authors.lastname: Brownell
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Rothbard
authors.forename: Charlene
authors.initials: C
authors.lastname: Chen
authors.forename: Rose M
authors.initials: RM
authors.lastname: Ko
authors.forename: Marta P
authors.initials: MP
authors.lastname: Pereira
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Albers
authors.forename: Lawrence
authors.initials: L
authors.lastname: Steinman
authors.forename: Gary K
authors.initials: GK
authors.lastname: Steinberg
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000276:immunology; D051379:Mice; D020521:Stroke / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D038203:alpha-Crystallin B Chain / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D038203:alpha-Crystallin B Chain